欢迎深度融入本土研发 龚正会见丹麦诺和诺德公司董事会主席龙海歌一行

Group 1 - The core viewpoint emphasizes Shanghai's commitment to developing the biopharmaceutical industry as one of its three key leading industries, highlighting its innovation resources and industry scale [1] - Shanghai aims to enhance its technological innovation capabilities in the biopharmaceutical sector and promote international development, inviting global companies like Novo Nordisk to participate and integrate into local R&D and supply chains [1] - Novo Nordisk expresses confidence in Shanghai's vision to become a global leader in life sciences and healthcare, committing to deepen cooperation with local government and academic institutions to address chronic disease prevention and treatment [1] Group 2 - Novo Nordisk is a globally recognized biopharmaceutical company, ranked 368th in the Fortune Global 500, with established regional headquarters and open innovation centers in Shanghai [2]